Descemetorhexis combined with phacoemulsification in eyes with decompensated Fuchs' corneal endothelial dystrophy

Session Details

Session Title: Combined Cataract Surgery & Practice Styles

Session Date/Time: Sunday 15/09/2019 | 14:00-16:00

Paper Time: 14:06

Venue: Free Paper Forum: Podium 2

First Author: : K.Khripun RUSSIA

Co Author(s): :    Y. Nizametdinova                             

Abstract Details

Purpose:

The purpose of this study was to describe the results of 5-mm central descemetorhexis combined with phacoemulsification in eyes with decompensated Fuchs corneal endothelial dystrophy.

Setting:

Saint Petersburg State Hospital № 2, Saint Petersburg, Russia.

Methods:

A 5-mm central descemetorhexis was performed in 4 patients with coexisting decompensated Fuchs dystrophy and cataract who underwent combined phacoemulsification and descemetorhexis without endothelial transplantation (DWEK). All patients had central bullous keratopathy, undetectable central endothelial cell count, healthy peripheral corneal endothelium. To assess corneal edema and pachymetry was used anterior segment OCT «Casia» (SS – 1000, Tomey) in the 10 mm zone within a 6-month follow-up. In addition to the classical post-operative treatment all patients were treated with 3% sodium chloride hypertonic eye drops.

Results:

Preoperative central corneal thickness was 616±21 µm. Six months after surgery, central corneal thickness became 540±34 µm. Peripheral corneal thickness was not significantly different pre- and postoperatively. In all patients, stromal edema corresponded to the diameter of the descemetorhexis and decreased an associated visual acuity for 3-6 months. Following the surgery vision (BCVA) improved to 0,3±0,1 at 6 months. The use of 3% sodium chloride in the early postoperative period provides rehabilitation of patients and reduces subjective complaints

Conclusions:

DWEK combined with phacoemulsification is a perspective technology which can help to restore corneal transparency and increase visual acuity in patients with endothelial corneal dystrophy.

Financial Disclosure:

None